FDA Panel Votes to Keep Avandia on Shelves

Controversial diabetes drug still faces heart-attack link

By Sam Biddle, Newser Staff

Posted Jul 30, 2007 5:38 PM CDT

(Newser) – An FDA panel said today that GlaxoSmithKline's diabetes drug Avandia should remain in drugstores, despite earlier evidence the pill ups heart failure risks. Glaxo has defended its drug, countering that the risks associated with the popular Avandia are the same as those of other diabetes... Read full story »

COMMENTS

Read the comment policy

You need to Log in to Newser to comment. Don't have an account yet? Sign up now!

There are no comments

A snapshot of the day's best news stories.

View Larger Grid

All Today Yesterday Pick a Date

What's Popular Now on Facebook

Miami Face-Eater Identified

'Serpent Pastor' Dies of Snake Bite

Wall Street Journal (Source Grid »)

More on the Avandia controversy
Wall Street Journal

FDA critic adamant about removing Avandia
Reuters

US • Health • Money

FDA • health • drugs • diabetes • GlaxoSmithKline • Avandia • safety • heart failure

More Newser Stories

Feds Further Link Avandia to Heart Risk

FDA, Senate reports lambaste GlaxoSmithKline, want to yank drug

(NEWSER) - Some 800 people every month suffer heart attacks or heart failure because of the diabetes medication Avandia, according to government reports obtained by the New York Times . Under fire since 2007, the GlaxoSmithKline drug was linked to 304 deaths in the final quarter of last year and hundreds of thousands still take it. Avandia “should be removed from the market," concludes one FDA study unequivocally. More»

Controversy Rages Over Diabetes Drug's Heart Risks

FDA official says superiors ordered her to back off serious warning

(NEWSER) - Troubling questions about the diabetes drug Avandia persisted yesterday as an FDA official revealed that she was barred from recommending a critical warning about the medication, the Times reports. In the run-up to congressional hearings that began today, manufacturer GlaxoSmithKline rushed to disseminate interim clinical findings in hopes of blunting the controversy. More»

Drug Company Nemesis Strikes Again

Crusading cardiologist took on Vioxx, now Avandia, for heart risks

(NEWSER) - The doctor who helped to raise concerns about the painkiller Vioxx is back—with the study released earlier this week linking the same company's popular diabetes drug, Avandia, to higher risk of heart attacks. The Wall Street Journal looks at 58-year-old cardiologist Steven Nissen's role in identifying and publicizing drug risks. More»

Diabetes Drug Ups Heart Risk

New study documents dangers of Avandia, but company nixes recall

(NEWSER) - A popular diabetes drug may increase heart attack risks, a study reported in the New England Journal of Medicine concludes. Patients who took Avandia, which treats Type 2 diabetes, were 43% more likely to have a heart attack than those who took a placebo, the Cleveland Clinic study found. More»

FDA Panel: Keep Avandia on Market

But it may get warning label on heart risks

(AP) - A majority of federal health experts has voted to keep the controversial diabetes pill Avandia on the market despite evidence that it increases the risk of heart attack. A panel of Food and Drug Administration advisers voted 20-12 against withdrawing GlaxoSmithKline's once-blockbuster drug. The agency is not required to follow the group's advice, but it usually follows the advice of its advisory committees. More»

NEWS FROM OUR PARTNERS

What is Newser?

Face it: there's too much news. At Newser, we choose the most thought-provoking and entertaining stories from hundreds of US and international sources and reduce them to a headline, picture, and two paragraphs. And we do it 24/7—you can come back morning, noon, night (and in between) for something new that matters. Read less, know more.

Learn more »

Partnering with: Slate

View Newser on the mobile website

FDA Panel Votes to Keep Avandia on Shelves

Controversial diabetes drug still faces heart-attack link

FDA • health • drugs • diabetes • GlaxoSmithKline • Avandia • safety • heart failure

MOST POPULAR STORIES

[ By Views ]

[ By Comments ]

More Newser Stories

Feds Further Link Avandia to Heart Risk

FDA, Senate reports lambaste GlaxoSmithKline, want to yank drug

Controversy Rages Over Diabetes Drug's Heart Risks

FDA official says superiors ordered her to back off serious warning

Drug Company Nemesis Strikes Again

Crusading cardiologist took on Vioxx, now Avandia, for heart risks

Diabetes Drug Ups Heart Risk

New study documents dangers of Avandia, but company nixes recall

FDA Panel: Keep Avandia on Market

But it may get warning label on heart risks

About Us

Site

Community

Site Maps

Tools

More News

What is Newser?